EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beauvericin Exerts Antitumor Effects on Multiple Myeloma by Disrupting the USP9X-Bcl-2 Interaction to Promote Bcl-2 Degradation

Rui Jin, Runfeng Ni, Ning Ding, Yuchen Tao, Shuyang Cai, Yirong Shi, Milin Liu, Yirong Chen, Letian Yu, Jiahui Lu

Frontiers in Bioscience-Landmark · 2026

DOI: 10.31083/fbl51975 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2026. Verfasst von Rui Jin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 200071 Sha…. Hauptthemen laut MEDLINE: Depsipeptides, Multiple Myeloma, Proto-Oncogene Proteins c-bcl-2, Antineoplastic Agents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background:Beauvericin is a cyclic hexadepsipeptide derived from Bombyx batryticatus. It is known as Jiangcan in traditional Chinese medicine and has diverse pharmacological properties, including antitumor, antiviral, insecticidal, and antibacterial effects. However, its specific mechanisms against multiple myeloma (MM) are not fully understood. The aim of this study was to elucidate the mechanism of beauvericin in MM.Methods:This study utilized the mouse Sp2/0 cell line, the human U266 cell line, and a subcutaneous tumor allograft model in C57BL/6J mice. Flow cytometry was employed to evaluate apoptosis, and the Cell Counting Kit-8 (CCK-8) assay was used to measure cellular viability. Network pharmacology was employed for target prediction, followed by molecular docking analyses to confirm drug-target interactions. The protein expression levels of Ubiquitin-Specific Protease 9X (USP9X) and Bcl-2 were assessed by Western blotting following USP9X knockdown. Additionally, co-immunoprecipitation assays were performed to evaluate whether beauvericin modulates the Bcl-2/USP9X interaction and affects Bcl-2 ubiquitination. The antitumor effects of beauvericin were further evaluated through in vivo experiments.Results:Network pharmacology analysis identified 82 MM-related target genes for beauvericin. These included key targets such as Caspase-3, Bcl-2, Matrix metallopeptidase 9 (MMP9), and Caspase-8, which may contribute to the anti-MM effects of beauvericin. Molecular docking revealed strong affinity and stability between beauvericin and Bcl-2. In vitro experiments confirmed that beauvericin inhibits MM cell proliferation, promotes apoptosis, and enhances Bcl-2 ubiquitination and degradation by disrupting the interaction between the deubiquitinating enzyme USP9X and Bcl-2. In vivo studies demonstrated that beauvericin treatment suppressed the growth of subcutaneous MM tumors C57BL/6J mice.Conclusion:Beauvericin may exert its anti-MM effects by disrupting the USP9X-Bcl-2 interaction, thereby promoting Bcl-2 ubiquitination and degradation, and inducing cell apoptosis in MM cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DepsipeptidesMultiple MyelomaProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsAnimalsHumansMiceApoptosisCell Line, TumorMolecular Docking SimulationCell ProliferationMice, Inbred C57BLProteolysisUbiquitination

Stichwörter der Autor:innen

Bcl-2USP9Xapoptosisbeauvericinmultiple myelomanetwork pharmacologyubiquitination

Substanzen

DepsipeptidesbeauvericinProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsBCL2 protein, human

Autor:innen und Institutionen

  • Institute of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 200071 Shanghai, China.
  • Clinical Hematology Center and Institute of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 200071 Shanghai, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Jin, R., Ni, R., Ding, N., Tao, Y., Cai, S., Shi, Y., Liu, M., Chen, Y., Yu, L., & Lu, J. (2026). Beauvericin Exerts Antitumor Effects on Multiple Myeloma by Disrupting the USP9X-Bcl-2 Interaction to Promote Bcl-2 Degradation. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl51975

Vancouver

Jin R, Ni R, Ding N, Tao Y, Cai S, Shi Y, et al. Beauvericin Exerts Antitumor Effects on Multiple Myeloma by Disrupting the USP9X-Bcl-2 Interaction to Promote Bcl-2 Degradation. Frontiers in Bioscience-Landmark. 2026. doi:10.31083/fbl51975

BibTeX
@article{Jin2026,
  author = {Jin, Rui and Ni, Runfeng and Ding, Ning and Tao, Yuchen and Cai, Shuyang and Shi, Yirong and Liu, Milin and Chen, Yirong and Yu, Letian and Lu, Jiahui},
  title = {Beauvericin Exerts Antitumor Effects on Multiple Myeloma by Disrupting the USP9X-Bcl-2 Interaction to Promote Bcl-2 Degradation},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  doi = {10.31083/fbl51975}
}
Kostenlos starten →